Samir Gharib is a successful biopharmaceutical and technology executive with nearly 15 years of experience. Over the course of his career, Samir has raised over $500 million to fund clinical research and development, pipeline expansion, and drug commercialization. Samir also played a key role in the development and FDA approval of Marqibo® for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Samir earned his MBA from the Haas School of Business at U.C. Berkeley, and is a licensed Certified Public Accountant (CPA) in the State of California.